ABCELLERA BIOLOGICS Cash Flow Conversion Efficiency

Latest as of June 2026: 0.029x

ABCELLERA BIOLOGICS cash flow conversion efficiency. Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has a cash flow conversion efficiency ratio of 0.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€25.92 Million ≈ $30.31 Million USD) by net assets (€896.02 Million ≈ $1.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of ABCELLERA BIOLOGICS (2021–2025)

Cash flow conversion efficiency of ABCELLERA BIOLOGICS from 2021 to 2025. This chart illustrates how ABCELLERA BIOLOGICS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABCELLERA BIOLOGICS (8QQ) stock price for real-time trading data and today's change.

ABCELLERA BIOLOGICS Cash Flow Conversion Ratio Explained

ABCELLERA BIOLOGICS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

ABCELLERA BIOLOGICS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of ABCELLERA BIOLOGICS ranked by their cash flow conversion efficiency. Also see ABCELLERA BIOLOGICS (8QQ) market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
China Communications Construction Company Limited F:CYY	-0.051x
Breville Group Ltd AU:BRG	-0.006x
Wynn Macau Limited F:8WY	N/A
Zhende Medical Co Ltd SHG:603301	0.017x
Nelnet Inc NYSE:NNI	0.038x
Infore Environment Technology Group Co Ltd SHE:000967	-0.009x
Hisense Kelon Electrical Holdings Co Ltd SHE:000921	0.104x
Société Anonyme des Bains de Mer et du Cercle des Étrangers à Monaco F:RJ8	0.037x

Annual Cash Flow Conversion Efficiency for ABCELLERA BIOLOGICS (2021–2025)

The table below shows the annual cash flow conversion efficiency of ABCELLERA BIOLOGICS from 2021 to 2025. Review ABCELLERA BIOLOGICS free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€966.90 Million ≈ $1.13 Billion	€-131.29 Million ≈ $-153.50 Million	-0.136x	-32.10%
2024-12-31	€1.06 Billion ≈ $1.23 Billion	€-108.56 Million ≈ $-126.91 Million	-0.103x	-169.95%
2023-12-31	€1.15 Billion ≈ $1.35 Billion	€-43.88 Million ≈ $-51.30 Million	-0.038x	-116.93%
2022-12-31	€1.23 Billion ≈ $1.44 Billion	€277.36 Million ≈ $324.26 Million	0.225x	-5.68%
2021-12-31	€1.03 Billion ≈ $1.20 Billion	€244.58 Million ≈ $285.94 Million	0.238x	--

About ABCELLERA BIOLOGICS

F:8QQ Germany Biotechnology

Market Cap

$4.02 Billion

€3.43 Billion EUR

Market Cap Rank

#4623 Global

#796 in Germany

Share Price

€10.60

Change (1 day)

-6.19%

52-Week Range

€2.49 - €12.80

All Time High

€44.98